Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting

• Published in: Scientific reports Vol. 13; no. 1; p. 7437
• Main Authors: Espíndola, Otávio Melo, Fuller, Trevon L., de Araújo, Mia Ferreira, Tort, Luis Fernando Lopez, Guaraldo, Lusiele, Calvet, Guilherme, Resende, Paola, Bonaldo, Myrna, Whitworth, Jimmy, Smith, Chris, Siqueira, Marilda, Brasil, Patrícia
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 08.05.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/250/2152/2153/1291; 631/326/596/4130; 692/699/255/2514; Adult; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; BNT162 Vaccine; COVID-19; COVID-19 - prevention & control; COVID-19 Vaccines; Disease transmission; Educational attainment; Ethnicity; Humanities and Social Sciences; Humans; Immunoglobulin G; Infections; Laboratories; Measles; multidisciplinary; Mutation; SARS-CoV-2 - genetics; Science; Science (multidisciplinary); Secondary schools; Severe acute respiratory syndrome coronavirus 2; Vaccination; Vaccine efficacy; Vaccines; Viral infections; Viruses
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-34035-9

COVID-19 vaccines have dramatically reduced rates of severe infection requiring hospitalization. However, SARS-CoV-2 variants have reduced vaccine effectiveness at preventing any symptomatic infection. This real-world study analyzed binding and neutralizing antibodies generated after complete vaccination and boosting across three vaccine platforms. Binding antibodies decayed most slowly in people under 60 with hybrid immunity. Neutralizing antibodies against Omicron BA.1 were reduced compared to other variants. The anamnestic anti-spike IgG response to the first boost was more pronounced than after the second boost. Monitoring of the effects of SARS-CoV-2 mutations on disease severity and the effectiveness of therapeutics is warranted.